Month: September 2025

When it comes to prostate cancer, risk assessment has to be “just right.” New research shows that combining PSA density with MRI scoring (PI-RADS) makes predictions far more accurate, reducing unnecessary biopsies while ensuring dangerous cancers aren’t missed. keep reading

Active Surveillance helps men with low-risk prostate cancer avoid overtreatment, but anxiety and repeated biopsies can take a toll. A new approach—Super Active Surveillance—combines MRI monitoring with focal therapy, offering peace of mind while keeping future treatment options open. keep reading

What’s harder—treating prostate cancer, or living with the knowledge it’s still inside you? Research shows Active Surveillance may lead to significant anxiety and depression for some patients, raising important questions about how to balance safety, treatment, and peace of mind. keep reading

Is PSA testing about to lose its crown? With ultrafast MRI proving faster, more accurate, and less anxiety-inducing, researchers say the balance may be tipping toward MRI as the new “king” of prostate cancer screening. keep reading

A recent study confirms that the new PI-FAB scoring system is highly reliable for evaluating MRI scans after focal therapy. With strong agreement among radiologists, PI-FAB offers patients and clinicians more confidence in long-term monitoring and peace of mind. keep reading

Your gut biome does more than aid digestion—it could influence your risk of cancer and your body’s response to treatment. Discover how trillions of microscopic organisms in your gut may be quietly shaping your prostate health—and what you can do to support them. keep reading

Focal therapy offers men a less invasive option with fewer side effects—but who should receive it? Updated guidelines reveal how doctors are defining the “best fit” patients, and why careful evaluation is critical to getting the best outcomes. keep reading

When facing a prostate cancer diagnosis, knowing how aggressive the disease is makes all the difference in treatment choices. A new large-scale study shows that Artificial Intelligence, working with MRI scans, may help predict tumor grade with surprising accuracy—promising more clarity for patients and their doctors. keep reading

Radiation doesn’t always mean the end of prostate cancer. Could focal therapy offer hope for recurrence? A new study on MRI-guided TULSA sheds light on benefits—and risks—that patients should know. keep reading

For years, studies hinted that metformin—a common diabetes drug—might help slow prostate cancer. But new results from the MAST trial show otherwise. Among men on Active Surveillance, metformin did not prevent disease progression compared to placebo, and side effects were more common. keep reading